In the fall of 2015, Elizabeth Holmes graced the cover of Forbes magazine as the youngest self-made female billionaire in history. She was 31 years old. Her company, Theranos, was valued at $9 billion. Its stated mission was breathtaking in its ambition: to revolutionize healthcare by performing hundreds of blood tests from a single drop of blood, drawn from a painless finger prick rather than a traditional needle in the vein. If the technology worked, it would democratize diagnostics, make blood testing cheap and accessible, and save countless lives through early detection of disease.
There was just one problem. The technology didn’t work. It had never worked. And Elizabeth Holmes knew it.
The Theranos story is not simply a tale of a startup that failed. Silicon Valley is littered with failed startups. Theranos was different because it operated in healthcare, where the stakes are measured not in lost dollars but in misdiagnoses, delayed treatments, and patients making life-altering medical decisions based on blood test results that were dangerously inaccurate. It is the story of what happens when the “fake it till you make it” culture of tech entrepreneurship collides with the unforgiving reality of human biology.
The Stanford Dropout
Elizabeth Holmes arrived at Stanford University in 2002 with a fierce intelligence and an even fiercer ambition. She was captivated by the potential of microfluidics — the science of manipulating tiny quantities of fluid — and began working in the lab of Channing Robertson, a professor of chemical engineering who would become one of her most vocal supporters.
By her sophomore year, Holmes had filed her first patent and dropped out of Stanford to found Real-Time Cures, which she soon renamed Theranos — a portmanteau of “therapy” and “diagnosis.” She was 19 years old. The pitch was irresistible: a device the size of a desktop printer that could run comprehensive blood panels from a tiny finger-prick sample, delivering results in minutes at a fraction of the cost of traditional lab testing.
Holmes was a mesmerizing fundraiser. She cultivated a deliberate mystique — always dressed in black turtlenecks in conscious imitation of Steve Jobs, speaking in a deep baritone that former colleagues would later say seemed affected. She assembled a board of directors that read like a who’s who of American power: George Shultz, Henry Kissinger, James Mattis, Sam Nunn, William Perry. These were titans of politics and defense, not healthcare or technology — people who could open doors but lacked the expertise to evaluate Theranos’s scientific claims.
Between 2004 and 2015, Holmes raised over $700 million from investors including Rupert Murdoch, the Walton family (heirs to the Walmart fortune), Betsy DeVos, and the Cox family. Not one of them conducted the kind of rigorous technical due diligence that would have revealed the fraud at the company’s core.
The Edison and the Minilab: Machines That Couldn’t
Inside Theranos’s Palo Alto headquarters, the reality was grim. The company’s proprietary blood-testing device — called the Edison — was plagued with problems. The finger-prick samples it collected were too small and too prone to contamination to produce reliable results. The miniaturized testing components generated wildly inconsistent readings. Internal quality-control tests showed failure rates that would be unacceptable in any clinical laboratory.
Rather than acknowledge these limitations and focus on solving them, Holmes and her partner — Ramesh “Sunny” Balwani, who served as Theranos’s president and COO — chose to conceal them. When Theranos couldn’t get accurate results from its own machines, it secretly ran samples on commercial analyzers manufactured by Siemens, modified to work with the small finger-prick volumes. Even these modified machines produced questionable results. Some tests were simply run on standard, unmodified Siemens equipment using venous blood draws — the very conventional method Theranos claimed to have made obsolete.
The deception extended to every level of the organization. Employees who raised concerns were silenced, threatened with lawsuits, or fired. Theranos maintained an atmosphere of extreme secrecy, compartmentalizing information so that no single employee could see the full picture. Balwani, who had invested $100 million of his own money and was romantically involved with Holmes (a relationship concealed from the board), ran the lab operations with an iron fist, berating and intimidating staff who questioned the technology’s performance.
The Walgreens Deal: Real Patients, Fake Results
In 2013, Theranos launched a partnership with Walgreens to offer blood testing at pharmacy locations in Arizona. It was the moment the company’s deceptions moved from the theoretical to the dangerous. Real patients were now receiving real test results from technology that Theranos knew was unreliable.
The consequences were predictable and devastating. Patients received results showing wildly abnormal values — PSA levels suggesting prostate cancer, blood clotting measurements indicating dangerous disorders — that turned out to be false. Others received normal results when they should have been flagged for serious conditions. Doctors made treatment decisions based on data that was essentially meaningless. In a healthcare system where a single misread blood test can lead to unnecessary surgery, missed diagnoses, or fatal treatment errors, Theranos was playing roulette with human lives.
Walgreens, which had invested $140 million in the partnership and built out “wellness centers” in dozens of stores, was kept deliberately in the dark about the technology’s limitations. When Walgreens executives requested to visit Theranos’s lab, they were refused. When they asked for validation data, they received carefully curated results that obscured the systemic failures.
The Wall Street Journal Investigation
The unraveling began with a tip. In early 2015, a former Theranos employee named Tyler Shultz — the grandson of board member George Shultz — contacted reporter John Carreyrou at the Wall Street Journal. Shultz had worked in Theranos’s lab and seen firsthand the discrepancies between what the company claimed and what its machines actually produced. He was terrified of retaliation but determined to expose the truth.
Carreyrou spent months investigating, cultivating additional sources within the company. When Theranos learned of the investigation, Holmes dispatched the company’s lawyers — led by the feared litigator David Boies, who had taken equity in Theranos rather than fees — to pressure the Journal into killing the story. They threatened Shultz and other whistleblowers with lawsuits. They hired private investigators to follow former employees.
None of it worked. On October 16, 2015, Carreyrou published his first article, revealing that Theranos was conducting the vast majority of its tests on conventional machines rather than its proprietary technology, and that the finger-prick tests it did run on its own devices were producing inaccurate results. The article triggered a cascade of investigations by the Centers for Medicare and Medicaid Services (CMS), the FDA, and the SEC.
The Collapse
Holmes fought back with everything she had. She appeared on television, gave defiant interviews, and insisted that Theranos’s technology was revolutionary and that the criticism was driven by competitors and short sellers. For a brief moment, her charisma held. Some investors and board members rallied behind her.
But the regulatory investigations were relentless. In January 2016, CMS inspectors found that Theranos’s Newark, California lab posed “immediate jeopardy to patient health and safety.” The lab was banned from performing blood tests for two years. Theranos was forced to void tens of thousands of test results — an extraordinary admission that the results patients and doctors had relied upon were unreliable.
Walgreens terminated its partnership and sued Theranos for $140 million. Investors filed lawsuits. The SEC opened a fraud investigation. One by one, the famous board members resigned. By 2017, Theranos’s valuation had been revised to zero. In June 2018, a federal grand jury indicted Elizabeth Holmes and Sunny Balwani on multiple counts of wire fraud and conspiracy.
The Trial and the Verdict
Holmes’s trial began in September 2021 in San Jose, California. The prosecution presented a meticulous case built on emails, internal documents, and testimony from former employees, investors, and patients. The evidence showed that Holmes had personally directed the creation of misleading reports sent to investors and partners, had affixed pharmaceutical company logos to validation reports those companies had never authorized, and had knowingly deployed unreliable technology on real patients.
Holmes took the stand in her own defense — a risky gambit. She claimed that she had believed the technology was on the verge of working, that she had relied on the expertise of others, and that she had been the victim of emotional and psychological abuse by Balwani, who she said had controlled her through intimidation and coercion during their secret relationship. Balwani denied the allegations.
On January 3, 2022, the jury found Holmes guilty on four counts of wire fraud — three related to defrauding investors and one count of conspiracy. She was acquitted on the charges related to defrauding patients. In November 2022, she was sentenced to 11 years and three months in federal prison. She reported to a minimum-security prison camp in Bryan, Texas, in May 2023.
Balwani was convicted on all twelve counts he faced — including fraud against both investors and patients — and sentenced to nearly 13 years in prison.
The Lessons of Theranos
Theranos was not a technology company that fell short of its ambitions. It was a fraud that used the language and aesthetics of Silicon Valley innovation to perpetuate a deception with real human consequences. Elizabeth Holmes did not fail to build a revolutionary blood-testing device; she knew it didn’t work and chose to deploy it anyway, putting patients at risk while lying to investors, partners, and regulators.
The scandal exposed the dangerous convergence of celebrity culture and venture capital — a world where a compelling founder narrative could substitute for scientific evidence, where prestigious board members provided credibility without scrutiny, and where the fear of missing out on the next Apple or Google overrode basic due diligence. Not one of Theranos’s investors asked to see independently validated test results before writing their checks.
Most importantly, Theranos showed that the “move fast and break things” ethos that drives Silicon Valley innovation cannot be applied to fields where lives are at stake. Software bugs can be patched. Misdiagnosed patients cannot be un-misdiagnosed. The boundary between ambition and recklessness is not always clear, but Theranos crossed it deliberately, knowingly, and repeatedly.
Watch the Full Story
Go Deeper
📚 Bad Blood: Secrets and Lies in a Silicon Valley Startup by John Carreyrou — The Pulitzer Prize-winning journalist who broke the Theranos story delivers the definitive account of the fraud, based on years of investigation and hundreds of interviews.
🎧 Listen free on Audible — Experience the full Theranos saga in audiobook form.
📖 Explore more stories like this on our Recommended Reading page.
More From The Ledger
- Wirecard — The payment processor that fooled Germany with fabricated billions
- General Electric — How financial engineering brought down an American icon
- FTX — Sam Bankman-Fried and the crypto empire built on customer funds
Browse all stories on our Stories page.
🔔 Subscribe to The Ledger on YouTube for new investigations every week.